PFE : A high-risk high-reward opportunity
The exponential growth of Pfizer during the COVID era can be attributed significantly to its role as a vaccine producer. However, the current levels of PFE are even lower than the pre-COVID trading price. The current stock price is approaching the lowest levels witnessed during the COVID-induced market crash. Consequently, almost all the increase in price driven by the COVID vaccine narrative is not reflected in the current stock price.
I perceive potential in Pfizer as a robust company at its current valuation.
I have entered the market twice at various levels, resulting in a total position size of approximately 1.85% of my capital. I am contemplating additional purchases to augment the position size to 2.5% of the capital. Will update underneath this post if and when I do so.
At present, my intention is to retain the position until the stock reaches its all-time high, presenting a potential upside move of about 122%.
I perceive potential in Pfizer as a robust company at its current valuation.
I have entered the market twice at various levels, resulting in a total position size of approximately 1.85% of my capital. I am contemplating additional purchases to augment the position size to 2.5% of the capital. Will update underneath this post if and when I do so.
At present, my intention is to retain the position until the stock reaches its all-time high, presenting a potential upside move of about 122%.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.